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Abstract
Background: Improved referral algorithms for children with non-severe pneumonia at the community level are
desirable. We sought to identify predictors of oral antibiotic failure in children who fulfill the case definition of
World Health Organization (WHO) non-severe pneumonia. Predictors of greatest interest were those not currently
utilized in referral algorithms and feasible to obtain at the community level.
Methods: We systematically reviewed prospective studies reporting independent predictors of oral antibiotic failure
for children 2–59 months of age in resource-limited settings with WHO non-severe pneumonia (either fast breathing
for age and/or lower chest wall indrawing without danger signs), with an emphasis on predictors not currently utilized
for referral and reasonable for community health workers. We searched PubMed, Cochrane, and Embase and
qualitatively analyzed publications from 1997–2014. To supplement the limited published evidence in this subject
area we also surveyed respiratory experts.
Results: Nine studies met criteria, seven of which were performed in south Asia. One eligible study occurred
exclusively at the community level. Overall, oral antibiotic failure rates ranged between 7.8-22.9 %. Six studies
found excess age-adjusted respiratory rate (either WHO-defined very fast breathing for age or 10–15 breaths/min
faster than normal WHO age-adjusted thresholds) and four reported young age as predictive for oral antibiotic
failure. Of the seven predictors identified by the expert panel, abnormal oxygen saturation and malnutrition were
most highly favored per the panel’s rankings and comments.
Conclusions: This review identified several candidate predictors of oral antibiotic failure not currently utilized in
childhood pneumonia referral algorithms; excess age-specific respiratory rate, young age, abnormal oxygen saturation,
and moderate malnutrition. However, the data was limited and there are clear evidence gaps; research in rural,
low-resource settings with community health workers is needed.
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Background
Healthcare providers in resource-limited countries use
practical, standardized case management guidelines to
diagnose pneumonia [1]. Although mortality reductions
of 36 % have been attributed to standardized manage-
ment, pneumonia remains the second leading cause of
childhood death globally with nearly one million deaths
annually [2]. Three-quarters of all deaths occur in Africa
and Asia, and it is estimated that a majority of all child-
hood pneumonia deaths occur outside of the hospital [3,
4]. Incomplete antibiotic coverage and care-seeking delays
negatively influence pneumonia outcomes in low-resource
settings and improvements have been inconsistent and dif-
ficult to sustain [4].
The World Health Organization (WHO) recommends
expansion of basic healthcare beyond traditional facil-
ities to community health workers (CHWs). This strat-
egy, called ‘integrated Community Case Management’
(iCCM), includes childhood pneumonia care [5]. iCCM
can address gaps in antibiotic access and care seeking
delays by providing antibiotics earlier in a pneumonia ill-
ness when the disease is more responsive to treatment
[5, 6]. Likewise, iCCM can permit earlier referral if treat-
ment fails - defined as disease persistence or progression
despite antibiotics. Evidence from Zambia and Pakistan
has demonstrated improved childhood pneumonia anti-
biotic coverage and reduced treatment failure with iCCM
[7–9]. As a result, iCCM expansion is a key strategy
against childhood pneumonia [5, 6].
Despite iCCM’s potential there are challenges, such as
sustaining quality of care. CHWs receive limited training
and are difficult to supervise in remote areas [5, 6]; con-
sistent supervision and retraining is likely important for
successful iCCM pneumonia management to ensure stan-
dardized recording of subjective clinical danger signs [10].
Strengthening CHW decision-making and identification
of higher-risk patients, including those that do not meet
current referral criteria, could reduce incorrect pneumonia
diagnosis, antibiotic prescription, and referrals. Mobile
health, or mHealth, may help to address these weaknesses
[11]. mHealth utilizes user-friendly software compatible
with mobile phones for healthcare delivery and capitalizes
on mobile networks with wide coverage and usage in de-
veloping countries [11]. New mHealth applications that
provide an array of performance support for CHWs are in
development [12, 13].
An iCCM mHealth mobile phone application could as-
sist CHWs to identify two groups of children with pneu-
monia; (1) those who meet current referral criteria but
are mis-classified, and (2) those who do not meet current
referral criteria but are still at greater risk for treatment
failure based upon their initial clinical assessment. Both
groups of children could then be referred for more appro-
priate treatment or be flagged for closer community-based
monitoring. An improved referral mHealth tool could pro-
vide the result as a simple audio recommendation trans-
lated into the preferred local language, allowing both
the CHW and caregiver to hear the recommendation.
Facilitating objective decision-making by CHWs with a
mHealth tool could complement existing guidelines to
expand appropriate, timely antibiotic coverage and fur-
ther reduce life-threatening treatment delays.
This systematic review and expert opinion survey aimed
to identify predictors of WHO non-severe pneumonia
treatment failure that are not currently used in referral al-
gorithms and are also realistic for CHWs. The ultimate
aim of a prediction algorithm would be to facilitate im-
proved referral pathways originating from the community
level, leading both to improved antibiotic stewardship and
decreased morbidity and mortality.
Methods
Systematic review
We conducted a systematic review in accordance with
PRIMSA (see Additional file 1) [14]. All studies from Janu-
ary 1, 1997 - June 25, 2014 listed in PubMed, Cochrane
Central Register of Controlled Trials, and Embase were
eligible. The following search terms were used: pneumo-
nia; predictors or risk factors or prognostic; treatment fail-
ure or death; and Africa or Asia or developing country.
These were combined with the following search filters:
clinical trial, humans, and infant or preschool ages. No
language restrictions were applied. We conducted the
search on June 25, 2014. We also conducted a supplemen-
tary, non-systematic search that did not filter for geo-
graphical region. Please see Additional file 2 for these
findings.
Titles and abstracts were reviewed twice and those
which both reviewers agreed were relevant underwent
full text review. Reference lists of reviewed manuscripts
were screened for additional studies. Eligibility criteria
included: 1) Study design: Prospective observational
studies and clinical trials. 2) Participants: Aged 2–59
months treated with oral antibiotics for WHO-defined
non-severe pneumonia per the 2013 revised WHO
guidelines (Fig. 1) [15]. 3) Data collection dates: 1997 or
more recent. The current WHO guidelines were for-
mally disseminated in 1997 [1]. 4) Geographic regions:
Africa and/or Asia, representing the highest burden of
disease. 5) Outcome: A priori defined treatment failure,
with statistical analysis for independent baseline clinical
predictors of treatment failure.
We used a structured data extraction tool to describe
key data from the eligible studies including: region, study
design, primary outcome, data collection dates, enroll-
ment criteria, treatment failure definition, sample size,
age range of participants, treatment failure rate, and in-
dependent predictors of treatment failure. The Cochrane
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Risk of Bias tool was used to qualitatively assess the risk
of bias in individual studies [16].
Expert opinion
We complemented the systematic literature review by
surveying childhood pneumonia experts. The experts
were all healthcare professionals experienced in child-
hood pneumonia in the African or Asian region across
hospital and community care settings, many with re-
search experience [17]. We used a modified Delphi con-
sensus process, administering two separate structured
phone interviews and a final electronic survey to 13 ex-
perts, concluding when a general consensus was reached
(see Additional file 3 for interview materials). Partici-
pants were asked to assess the potential role for a pneu-
monia treatment prognostic, including where in the
health system (the home, a community health clinic, or
the hospital) a prognostic would be best utilized.
The literature search provided the initial prognostic in-
dicators to test with interviewees, using WHO definitions
[15]. The panel was allowed to adjust these indicators, as
well as the definitions of them and we encouraged the
panel to use their own knowledge and experience. Fever
was modified to an axillary temperature >38.0 °C, high
blood lactate levels to >2 mmol/l, and low weight for age
as a standardized z score < −2. The definition of ‘human
immunodeficiency virus (HIV)-affected’ included HIV-
exposed children (i.e. born to an HIV-infected mother but
not HIV tested or previously tested HIV-negative with on-
going breastfeeding) or HIV-infected per standard guide-
lines [18].
The experts qualitatively and quantitatively estimated
each predictor’s potential value. Qualitative estimates of
each prognostic indicator’s value were allocated using an
ordinal scale (0 = unfavorable, 1 =minimally favorable, 2 =
favorable, 3 = highly favorable), along with any comments
regarding each indicator’s likely performance and feasibil-
ity. Panel members provided quantitative estimates by
assigning a childhood pneumonia mortality rate to com-
munity oral or parenteral hospital antibiotic treatment.
An anonymous summary of panel answers were pro-
vided to interviewees after the first interview and each
expert was encouraged to revise their answers after con-
sidering the panel’s overall results. For the final survey,
the expert opinion results were rephrased into binary
yes/no questions to determine a final consensus. This re-
search was approved by the Johns Hopkins Institutional
Review Board (IRB00047406) and written consent was
obtained from survey participants.
Results
Systematic review
Our search yielded 7,649 studies; of these, 59 manu-
scripts were retrieved for full text review. Nine studies
2-59 month old with cough 
and/or difficulty breathing
Fast breathing for age only Chest wall-indrawing only
No ‘danger signs’ 
• convulsions
• lethargy
• central cyanosis/SpO2<90%
• head nodding
• grunting
• severe chest wall-indrawing
• inability to drink/breastfeed
Fast breathing for age 
plus chest wall-indrawing
WHO non-severe 
pneumonia
Fig. 1 2013 World Health Organization non-severe pneumonia case definition
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met all eligibility criteria, including quality control, and
were qualitatively analyzed (Fig. 2). We found no publi-
cations that included children with fast breathing and
lower chest indrawing (LCI)-defined pneumonia together,
probably because the WHO guidelines were only recently
revised and disseminated in 2013.
Table 1 summarizes the six studies reporting predic-
tors of oral antibiotic failure in fast breathing non-severe
pneumonia [19–24]. All studies were from developing
countries in south Asia. Five of the six studies included
amoxicillin treatment and only one included community
clinics. Five studies defined treatment failure as either a
persistence of fast breathing after 3–5 days or disease
progression (development of LCI or danger signs) be-
tween 1–5 days after antibiotic initiation. One study in-
cluded peripheral oxygen saturation (SpO2) less than
90 % in the definition of treatment failure. The propor-
tion of children that failed oral antibiotic treatment
ranged from 7.8 % to 22.9 %. Three studies identified
baseline excess age-specific respiratory rate, and two
studies found history of difficulty breathing, age, and ill-
ness duration of ≥3 days as independent predictors of
oral antibiotic failure.
Table 2 summarizes the three studies reporting independ-
ent predictors of oral antibiotic failure in LCI non-severe
pneumonia [25–27]. Two studies were multi-country with
sites in Africa. In two of the three studies, treatment failure
was assigned on day six after antibiotic initiation. Treat-
ment failure rates for the three studies ranged from 8.1 %
to 19.3 %. All studies found young age and very fast breath-
ing at baseline to be independent predictors of treatment
failure. One study collected SpO2 measurements and found
low baseline SpO2 to predictive; another study found mal-
nutrition to be predictive of treatment failure.
Expert opinion
Of the 13 experts interviewed, eight reported experience
in Africa, four in Asia, and one in both. All interviewees
agreed that the development of a pneumonia treatment
prognostic could significantly advance childhood pneu-
monia care and that the community-level was the most
attractive setting for implementation.
The panel qualitatively evaluated seven prognostic in-
dicators for performance and feasibility at the commu-
nity level (Table 3). Abnormal SpO2 and malnutrition
were ranked highest while fever and high blood lactate
Records identified through database search: 
Titles, abstracts, and key words reviewed
(n= 7,649)
Abstracts excluded after initial review 
due to lack of relevancy
(n= 7,535)
Abstracts screened in detail
(n= 114)
Abstracts excluded for not 
meeting inclusion criteria
(n= 58)
Full-text articles reviewed for 
eligibility
(n= 56)
Number of records 
identified through full-text 
article reference lists
(n= 3)
Full-text articles included in 
the review
(n= 9)
Fast-breathing WHO 
non-severe pneumonia
[Table 1]
(n= 6)
Chest-indrawing WHO 
non-severe pneumonia
[Table 2]
(n= 3)
Full-text articles excluded
(n= 50)
• Independent predictors not 
reported (n= 20)
• Predictors assessed not 
appropriate for community 
treatment (n= 1)
• Incorrect subject age range (n= 4)
• Included intravenous antibiotics 
(n= 22)
• Subjects with wheeze only (n= 1)
• Duplicate data used and treatment 
failure definition determined 
retrospectively (n= 1)
• Dates of data collection outside 
range (n=1)
Fig. 2 Flow diagram of study identification and selection
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Table 1 Independent predictors of oral antibiotic failure in fast breathing WHO non-severe childhood pneumoniaa
Study overview Awasthi S et al. CATCH UP MASCOT Agarwal G et al. Noorani QA et al. Hazir T et al.
Region (country) Asia (India) Asia (Pakistan) Asia (Pakistan) Asia (India) Asia (Pakistan) Asia (Pakistan)
Data collection
dates
2004–2006 1998–1999 1999–2001 2000–2002 2000–2001 2005–2008
Enrollment criteria 2–59 months old 2–59 months old 2–59 months of
age
2–59 months of age 2–59 months of
age
2–59 months of
age
Study design Cluster randomized
study
Randomized
multicenter
equivalency study
Randomized
multicenter
equivalency study
Randomized
multicenter
equivalency study
Multicenter
observational study
Randomized
multicenter
equivalency
study
Intervention
arm
Oral amoxicillin 31–
51 mg/kg/day for
3 days
Oral amoxicillin
50 mg/kg/day for
5 days
Oral amoxicillin
45 mg/kg/day for
3 days
Oral amoxicillin 31–
54 mg/kg/day for
3 days
- Placebo for
3 days
Control arm (or
standard of
care)
Oral trimethoprim
(7–11 mg/kg/day)-
sulfamethoxazole for
5 days
Oral trimethoprim
(8 mg/kg/day)-
sulfamethoxazole
for 5 days
Oral amoxicillin
45 mg/kg/day for
5 days
Oral amoxicillin 31–
54 mg/kg/day for
5 days
Oral trimethoprim
(8 mg/kg/day)-
sulfamethoxazole
for 5 days
Oral amoxicillin
45 mg/kg/day
for 3 days
Blinding No Yes Yes Yes - Yes
Study site
types
Health centers Tertiary care and
secondary-level
hospitals, and
health center
Tertiary care and
secondary-level
hospitals
Tertiary care hospitals Health centers Tertiary care
hospitals
Number of
sites
14 8 7 7 14 4
Primary
outcome
Treatment failure Equivalency Equivalency Equivalency Treatment failure Equivalency
Treatment failure definition
Day of
assignment
Day 3 (intervention);
Day 5 (control)
Days 3 to 5 Day 5 Days 3 to 5 Day 5 Day 3
Respiratory
ratea
Yes, elevated for age
(days 3–5)
Yes, +/−5 breaths/
min or higher
versus enrollment
(days 3–5)
Yes, elevated for
age (days 3–5)
Yes, elevated for age
(days 3–5)
Yes, +/−5 breaths/
min or higher
versus enrollment
(days 3–5)
No
Fever >38 °C
and LCI
No No No No No No
Fever >38 °C Yes (days 3–5) No No No No No
LCI Yes (days 1–5) Yes (days 3–5) Yes (days 1–5) Yes (days 1–5) Yes (days 1–5) Yes (days 1–3)
Convulsions Yes (days 1–5) Yes (days 3–5) Not specified Yes (days 1–5) Not specified Yes (days 1–3)
Abnormally
sleepy
Yes (days 1–5) Yes (days 3–5) Not specified Yes (days 1–5) Not specified Yes (days 1–3)
Inability to
drink
Yes (days 1–5) Yes (days 3–5) Not specified Yes (days 1–5) Not specified Yes (days 1–3)
Stridor in calm
child
Yes (days 1–5) Yes (days 3–5) No No No Yes (days 1–3)
Malnutrition No Yes (days 3–5) No No No Yes (days 1–3)
Cyanosis Yes (days 1–5) No Yes No Yes No
SpO2 No No No Yes, <90 % (on day 3
only)
No No
Antibiotic
change
No Yes (days 3–5) Yes (days 1–5) No Yes (days 1–5) No
Hospitalization No Yes (days 1–5) No No No No
Lost to follow-
up
Yes (days 3–5) Yes (days 3–5) No Yes (days 1–5) Yes (days 5–11) No
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levels were lowest. Abnormal SpO2 was judged to be ob-
jective, although the panel identified the need for a robust,
precise, low-cost pulse oximeter for young children. Mal-
nutrition was also valued by the experts as it is likely to
have a high positive predictive value and the feasibility of
reliable malnutrition screening was attractive, with tools
such as tapes and scales being simple, accurate, and rela-
tively inexpensive.
The panel’s quantitative performance estimates for
each prognostic indicator are presented in Table 4. Re-
gardless of setting, children that are malnourished, HIV-
affected or have an abnormal SpO2, were estimated to
be at the highest mortality risk by the panel. Estimated
median mortality rates of community treatment with
amoxicillin for children with abnormal SpO2, malnutri-
tion, or an HIV-affected status ranged from 15.5–20 %.
Discussion
WHO guidelines standardize pneumonia management
in low-resource settings and stratify pneumonia severity
according to the presence of severe clinical features [1,
15]. Currently, these guidelines do not further categorize
non-severe pneumonia patients according to their treat-
ment failure risk even though some children with non-
severe disease have failure rates as high as 23 % [20].
Given the increased decentralization of pneumonia care
to CHWs, improving baseline risk stratification with ob-
jective clinical measures may be an important next step
for reducing pneumonia morbidity. To assist in algo-
rithm development, we performed a systematic review
and surveyed experts to identify predictors of oral anti-
biotic failure in children that fit the WHO case defin-
ition for non-severe pneumonia (2013 guidelines) [15].
We placed the greatest emphasis on predictors not cur-
rently incorporated into referral algorithms and those
that were also measureable by CHWs. From the litera-
ture and expert review, we found some agreement for
excess age-specific respiratory rate, abnormal baseline
SpO2 and moderate malnutrition as important predic-
tors of treatment failure. However, the literature was
limited and highlighted several key evidence gaps, and
there were notable differences between those predictors
Table 1 Independent predictors of oral antibiotic failure in fast breathing WHO non-severe childhood pneumoniaa (Continued)
Study
withdrawal
Yes (days 1–5) No No Yes (days 1–5) No No
Death Yes (days 1–14) Yes (days 1–5) Yes (days 1–5) Yes (days 1–5) Yes (days 1–5) Yes (days 1–5)
Study participants and description
Sample sizeb 2009 1459 1953 2188 944 873
Age 2–11 months 594/2009 (29.6 %) 732/1459 (50.2 %) 1051/1953 (53.8 %) 954/2188 (43.6 %) 334/944 (35.4 %) 573/873 (65.6 %)
Age 12–59
months
1415/2009 (70.4 %) 727/1459 (49.8 %) 902/1953 (46.2 %) 1234/2188 (56.4 %) 610/944 (64.6 %) 300/873 (34.4 %)
Treatment failure
rateb
234/2009 (11.6 %) 256/1459 (17.5 %) 364/1953 (22.9 %) 225/2188 (10.3 %) 110/944 (11.6 %) 68/873 (7.8 %)
Independent
predictors of
treatment failure
OR (95 % CI)c,d
Diarrhea, 1.65
(1.24–2.19)
History of difficulty
breathing, 1.61
(1.13–2.15)
Excess respiratory
rate >10 breaths/
min for agea, 1.4
(1.1–1.9)
Excess respiratory
rate >10 breaths/min
for agea, 2.89 (1.83–
4.55)
Excess respiratory
rate ≥15 breaths/
min for agea, 2.0
(1.2–3.4)
History of
difficulty
breathing, 2.86
(1.29–7.23)
Age 12–59 months,
1.5 (1.12–1.91)
Antibiotic non-
adherence, 4.5
(95 % CI 2.9–7.0)
Antibiotic non-
adherence, 11.57
(7.4–18.0
Wheeze on
examination, 1.7
(1.1–2.6)
Temperature
>37.5 °C at
enrollment, 1.99
(1.37–2.90)
Illness >3 days, 1.4
(1.03–1.8)
Illness ≥3 days, 1.7
(1.3–2.1)
RSV, 1.95 (1.0–3.8)
Age 2–11 months,
1.7 (1.1–2.1)
Persistent vomiting,
1.4 (1.0–2.0)
Serious adverse event or drug reaction, and new comorbid condition were not considered in the treatment failure definitions for any of the studies. WHO: World
Health Organization; LCI: lower chest wall indrawing; SpO2: peripheral oxygen saturation; OR: odds ratio; CI: confidence interval; RSV: human respiratory
syncytial virus
aRespiratory rate norms: <50 breaths/min for ages 2–11 months; <40 breaths/min for ages 12–59 months
bIf primary outcome of trial was equivalency or no difference was found then intervention and control arm data was combined
cMultivariate logistic regression modeling was performed to determine independent predictors of treatment failure in all included studies. CATCHUP trial modeled
age, history of difficulty breathing, duration of illness, and respiratory rate. The models were not reported for the MASCOT trial, Agarwal G et al., Noorani QA et al.,
Awasthi S et al., and Hazir T et al
dFor Hazir T et al. multivariate logistic regression modeling was performed on cumulative treatment failure data from day 5 although primary outcome data was
analyzed from day 3 treatment failure data
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Table 2 Independent predictors of oral antibiotic failure in chest indrawing WHO non-severe childhood pneumonia
Study
overview
Addo-Yobo E, Chisaka N et al. Hazir T, Fox LM et al. Addo-Yobo E, Anh DD et al.
Region
(countries)
Africa (Ghana, South Africa, Zambia) Asia (India,
Pakistan, Vietnam) South America (Columbia,
Mexico)
Pakistan (Asia) Africa (Egypt, Ghana) Asia
(Bangladesh, Vietnam)
Data
collection
dates
1999–2002 2005–2006 2005–2008
Enrollment
criteria
3–59 months 3–59 months 3–59 months
Study design Randomized multicenter equivalency study Randomized multicenter equivalency study Multicenter observational study
Intervention
arm
Oral amoxicillin 45 mg/kg/day for 5 days Oral amoxicillin 80–90 mg/kg/day for
5 days
-
Control arm
(or standard
of care)
Intravenous 200,000 IU penicillin G for 2 days
then oral amoxicillin 45 mg/kg/day for 3 days
(total 5 days)
Intravenous ampicillin 100 mg/kg/day for
2 days then oral amoxicillin for 3 days (total
5 days)
Amoxicillin 80–90 mg/kg/day for
5 days
Blinding No No -
Study site
type(s)
Pediatric department of tertiary care hospitals Pediatric department of tertiary care
hospitals
Pediatric department of tertiary care
and second-level hospitals, health
centers
Number of
study sites
9 7 5
Primary
outcome
Equivalence Equivalence Treatment failure
Treatment failure definition
Day of
assignment
Day 3 Day 6 Day 6
Respiratory
ratea
No No No
Fever >38 °C
and LCI
No Yes (days 3–6) Yes (day 3)
Fever >38 °C No Yes (day 6) Yes (day 6)
LCI Yes (day 3) Yes (day 6) Yes (day 6)
Convulsions Yes (days 1–3) Yes (days 1–6) Yes (days 1–6)
Abnormally
sleepy
Yes (days 1–3) Yes (days 1–6) Yes (days 1–6)
Inability to
drink
Yes (days 1–3) Yes (days 1–6) Yes (days 1–6)
Stridor in
calm child
No No No
Malnutrition No No No
Cyanosis Yes (days 1–3) Yes (days 1–6) Yes (days 1–6)
SpO2 <80 % at sea-level or <75 % below sea-level
(days 1–3)
No No
Antibiotic
change
Yes (days 1–3) No Yes (days 1–6)
Hospitalization No Yes, if related to pneumonia (days 1–6) No
Serious drug
reaction
Yes (days 1–3) No Yes (days 1–6)
Serious
adverse event
No Yes (days 1–6) No
Yes (days 1–3) Yes, if required antibiotic (days 1–6) Yes (days 1–6)
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supported by the literature and those favored by the
experts.
Our systematic review and expert survey yielded sev-
eral interesting comparisons. The panel strongly favored
abnormal SpO2 as a predictor, however, SpO2 was evalu-
ated in only two studies [21, 25], none of which exam-
ined SpO2 at community clinics or assessed less severe,
but still abnormal SpO2 ranges (90–94 %). Similarly,
malnutrition was highlighted by the panel but was only
found to be predictive for oral antibiotic failure in one
study conducted at tertiary hospital clinics [26]. Milder
degrees of malnutrition were not evaluated, and the ex-
perts defined malnutrition in the moderate range. Al-
though young age was found to be predictive in multiple
studies [20, 25–27], the experts did not recommend
young age as a candidate predictor. Haemophilus influ-
enzae type B (HiB) vaccine or pneumococcal conjugate
vaccine (PCV) status were not examined as predictors in
our systematic review since most studies were per-
formed before introduction of these vaccines, but it was
also not recommended by the panel. These differences
between the published literature and expert panel may
in part reflect the panel’s emphasis on personal experi-
ence to guide their answers and the overall lack of
publications meeting eligibility criteria. In addition, a
majority of the panel worked in Africa while in contrast
the published literature was heavily represented by Asia.
The systematic review suggested that fast breathing
and LCI pneumonia may be distinct groups with differ-
ent drivers and predictors of failure. Our review of the
literature consistently found excess age-specific respira-
tory rate as an important predictor in both LCI- and fast
breathing non-severe pneumonia [20–22, 25–27], but
abnormal baseline SpO2 and young age were clearer pre-
dictors of treatment failure in children solely with LCI
[25–27]. In those studies looking at fast-breathing de-
fined pneumonia, the independent predictors were less
consistent and included persistent vomiting, diarrhea,
wheeze, human respiratory syncytial virus infection and
history of difficult breathing; these may suggest a pri-
marily viral cause of illness. Other studies support the
notion that a low proportion of fast breathing pneumo-
nia cases may be due to bacterial pneumonia. Hazir and
colleagues reported that only 1.7 % of Pakistani children
with fast breathing pneumonia had a radiographic con-
solidation consistent with a bacterial etiology [28], and
the same group also published findings of equivalency
when fast breathing cases were treated with either
Table 2 Independent predictors of oral antibiotic failure in chest indrawing WHO non-severe childhood pneumonia (Continued)
New
comorbid
condition
Lost to follow-
up
Yes (days 1–3) Yes (days 1–6) Yes (day 6)
Study
withdrawal
Yes (days 1–3) Yes (days 1–6) No
Death Yes (days 1–3) Yes (days 1–14) Yes (days 1–6)
Study participants and description
Sample sizeb 1702 2037 823
Age: 3–11
months
1045/1669 (62.6 %) 1311/2037 (64.4 %) 562/873 (64.4 %)
12–59
months
624/1669 (37.4 %) 726/2037 (35.6 %) 310/873 (35.5 %)
Treatment
failure ratec
328/1702 (19.3 %) 164/2037 (8.1 %) 76/823 (9.2 %)
Independent
predictors of
treatment
failurec OR/RR
(95 % CI)
Age 3–11 months, 2.72 OR (95 % CI 1.95–3.79) Age 3–5 months, 3.22 OR, (95 % CI 1.87–5.52) Age 3–5 months, 1.96 RR (95 % CI
1.09–3.51)
Very fast breathing, 1.94 OR (95 % CI 1.42–2.65)d Very fast breathing, 1.65 OR (95 % CI
1.07–2.57)d
Very fast breathing, 12.5 RR (95 % CI
1.74–89.1)d
SpO2 < 90 %, 2.11 OR (95 % CI 1.6–2.78) Weight for age z score <−2, 1.79 OR (95 %
CI 1.23–2.60)
WHO: World Health Organization; IU: International Units; LCI: lower chest wall indrawing; SpO2: peripheral oxygen saturation; OR: odds ratio; RR: relative risk; CI,
confidence interval
aRespiratory rate norms: <50 breaths/min for ages 2–11 months; <40 breaths/min for ages 12–59 months
bIf primary outcome of trial was equivalency then intervention and control arm data was combined
cMultivariate logistic regression modeling was used by Addo-Yobo E, Chisaka N et al. and Hazir T while log-linear regression modeling was used by Fox LM et al.
Addo-Yobo E, Chisaka N et al. modeled age, very fast breathing, hypoxemia, and amoxicillin. Hazir T, Fox LM et al. modeled sex, age, breastfeeding, weight-for-age
z score <−2, very fast breathing, and treatment group (home vs hospital). Addo-Yobo E, Anh DD et al. modeled sex, age, and respiratory rate
dVery fast breathing defined as ≥70 breaths/min for ages 3–11 months and ≥60 breaths/min for ages 12–59 months
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placebo or amoxicillin [23]. At this time listening for
wheeze with a stethoscope or testing for respiratory syn-
cytial virus are not feasible for routine CHW care. The
results from this systematic review should be interpreted
within this context; LCI and fast breathing pneumonia
may differ etiologically and the published literature on
this subject has primarily focused on fast breathing
pneumonia (only three studies meeting eligibility criteria
for this work included LCI pneumonia).
Our systematic review found an overall paucity of
community-level data, potentially limited by publication
bias. However, we also found other important evidence
gaps. Firstly, it is likely that predictors will differ between
African and Asian populations, in part because HIV is
endemic in southern Africa and a key driver of treatment
unresponsive pneumonia [29]. However, our systematic
review demonstrated that African data is limited, with
only two studies including data from African countries.
These studies did not explore region as a predictor of
treatment failure, and did not report adjusting for region
in their multivariate models. The experts also did not ad-
dress this evidence gap since they did not explicitly factor
regional differences into their responses, although the ma-
jority of experts worked in Africa and this is likely to have
influenced their answers. The development of a sound
prognostic algorithm for the southern African region that
Table 3 Expert panel qualitative assessments of potential prognostic indicators
Prognostic indicator Overall favorability Selected performance comments Selected feasibility comments
Fever Unfavorable Low specificity for identifying children who will not fail
treatment
High feasibility since already implemented
and measurement tools simple
Rapid breathing Minimally favorable Normal range highly variable Measurement tools inaccurate
Low sensitivity for hypoxemic children Low feasibility with respect to sequential
monitoring of respiratory rates over time
Performance profile improves with sequential monitoring
of respiratory rates over time
Lower chest wall
indrawing
Favorable Low specificity for identifying children who will not fail
treatment
Subjective sign with variable inter-provider
agreement levels
Abnormal oxygen
saturation
Highly favorable High specificity for identifying children who will not fail
treatment
Objective measurement but inter-provider
agreement levels unknown
Later indicator decreases sensitivity for identifying children
who will fail treatment at the community-level
Robust, precise, low-cost point-of-care
instrument needed
Likely costly to implement and sustain
High blood lactate
levels
Unfavorable Low specificity for identifying children who will not fail
treatment
Point-of-care tool appropriate for
community use not available, likely costly
Very late indicator decreases sensitivity for identifying
children who will fail treatment at the community-level
Moderate
malnutrition
Highly favorable Mid-range sensitivity and specificity which likely improves
greatly in combination with other indicators
High feasibility since measurement tools
simple and accurate
High positive predictive value
HIV-affected Minimally favorable Geographically limited in relevancy (e.g. primarily in eastern
and southern Africa)
Low feasibility since difficult to obtain HIV
status at community-level (e.g. stigma)
High positive predictive value
HIV: Human Immunodeficiency Virus
Table 4 Expert panel quantitative assessments of potential prognostic indicators
Identified prognostic indicatora Mortality rate according to location of care received if prognostic indictor positive
Community treatment with oral amoxicillin Hospital treatment with parenteral antibiotics
Fever 0.5 % (0.5–1.0) 0.1 % (0.1–0.2)
Rapid breathing 1.0 % (1.0–2.0) 0.2 % (0.1–0.5)
Lower chest indrawing 5.8 % (5.1–7.4) 1.0 % (0.6–1.0)
Abnormal SpO2 15.5 % (11.3–23.0) 6.3 % (5.0–7.5)
Moderate malnutrition 20.0 % (18.5–25.0) 10.5 % (5.0–12.8)
HIV-infected or HIV-exposed status 16.5 % (15.0–20.0) 7.5 % (6.1–8.6)
IQR: interquartile range; SpO2: peripheral oxygen saturation
aLactate not assessed quantitatively
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accounts for HIV status may be challenging since HIV
stigma persists, particularly in more rural, intimate com-
munity settings where anonymous testing is difficult to
achieve [30]. Second, it is likely that pneumonia epidemi-
ology, and thus treatment failure predictors, will shift after
HiB vaccine and PCV introduction. However, data from
developing countries after full vaccine introduction is only
more recently becoming available [31]. Due to these limi-
tations in the literature, the findings from the literature re-
view need to be interpreted cautiously.
Although validated prognostic models that identify
higher risk pneumonia patients exist, only two studies
(both secondary analyses from the Amoxicillin Penicillin
Pneumonia International Study (APPIS) [25]) present
predictive models for children who fulfill the LCI non-
severe pneumonia case definition [32, 33]. Mamtani et
al. validated a clinical tool for predicting oral amoxicillin
failure in children with LCI pneumonia and no danger
signs, using the child’s age and excess age-specific re-
spiratory rate after 24 h of treatment to stratify patients’
risk [32]. Fu et al. predicted the risk of oral amoxicillin
treatment failure after 48 h, with the best performing
model including a second clinical evaluation after 12 h
of treatment and SpO2 [33]. However both studies likely
reflect different pneumonia epidemiology due to increas-
ing HiB and PCV availability and current treatment fail-
ure definitions have been simplified [26, 27]. The
feasibility of using models that rely on a single patient
observation for an extended period or multiple clinical
observations will need careful assessment at the CHW
level.
At this time more evidence is needed to demonstrate
effective use of pulse oximetry by CHWs, whether
milder degrees of altitude-adjusted hypoxemia (90–
94 %) are predictive of treatment failure, and if pulse ox-
imetry can be cost-effective at the community level in
low-resource countries where equipment maintenance
can be challenging. Several low-cost respiratory rate
counters, pulse oximeters and combination devices have
recently been developed or are in development for low-
resource settings [34–36]; there is an on-going evaluation
of the clinical performance, usability, and acceptability of
these devices currently underway by Malaria Consortium
(D. Hay Burgess, personal communication).
Conclusion
In conclusion, we found that young age, excess age-
specific respiratory rate, abnormal baseline SpO2 and
moderate malnutrition should be carefully considered
for an automated mHealth iCCM tool for predicting oral
antibiotic failure in children with pneumonia. However,
the evidence is currently limited. Additional formative
research to identify antibiotic failure predictors is needed
at the community-level, in HIV and non-HIV endemic
regions, with and without malaria, and that have intro-
duced the HiB vaccine and PCV. Modeling patient and
health system-level consequences of a prognostic, along
with a cost analysis of device scale-up, are important
next steps.
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